Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Trinidad & Tobago STEM News.
Press releases published on July 25, 2025

PharmAla Issues Q3 Financial Statements
TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA ( …

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic …

Leap Local Launches Map Pack SEO Service to Help Small Businesses Rank Higher on Google Maps
Greensboro, NC, July 25, 2025 (GLOBE NEWSWIRE) -- Leap Local, a digital marketing company dedicated to supporting local businesses, has launched its new Map Pack SEO service. The service is designed to improve visibility in Google’s Local 3-Pack, helping …

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025
DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a portfolio of novel multi-targeted …

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer
MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July …

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpoint Inidascamine continues to …

NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
TORONTO and HAIFA, Israel, July 25, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that the Falling Walls Foundation has named the Company a finalist in Falling …

Treatment.com AI Announces Non-Brokered Private Placement of up to C$3 million of Special Warrants and Units
Vancouver, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; 939: FRA) is pleased to announce that due to strong inbound interest from new and existing investors, it is …

POP BIO and CEPI announce collaboration for faster responses to Disease X
Buffalo, NY, July 25, 2025 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new collaboration to …

Advantage Solutions Announces Date for its Second Quarter 2025 Financial Results and Conference Call
ST. LOUIS, July 25, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ GS: ADV) announced today that it will release financial results for the second quarter at 7 a.m. EDT on Aug. 7, 2025, followed by a conference call at 8:30 a.m. EDT on the same …

Olymptrade Rolls Out Intuitive Trading Experience for First-Time Users
Kingstown, Saint Vincent and The Grenadines, July 25, 2025 (GLOBE NEWSWIRE) -- Olymptrade, a leading global trading platform, has launched a redesigned trading experience focused on simplifying the journey for first-time users. By addressing the common …

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non- …

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non- …

BitMart and Altrady Announce New Partnership for Enhanced Trading
Mahe, Seychelles, July 25, 2025 (GLOBE NEWSWIRE) -- BitMart, a leading global cryptocurrency exchange, is thrilled to announce its strategic integration with Altrady, a powerful cryptocurrency trading platform designed to streamline trading across multiple …

DebitMyData Closes Oversubscribed Seed Round- Launches $1B Human Energy Grid Global Expansion
DebitMyData™ Logo FORT LAUDERDALE, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- DebitMyData™, Inc.—the powerhouse has closed a seed round at more than twice its original target. This surge of investor confidence paves the way for a bold, billion-dollar global …

Future CX Announces Strategic MOU With Epic Lanka and Global Launch of Blockchain-Based Security Suite BethelZKPe
SYDNEY, July 25, 2025 (GLOBE NEWSWIRE) -- Future CX has announced the global launch of BethelZKPe™️, its proprietary blockchain-powered data security suite, alongside the signing of a strategic Memorandum of Understanding (MOU) with Epic Lanka (Pvt) Ltd. …

Centex Technologies Welcomes Former Texas A&M University System Chancellor John Sharp as Strategic Advisor
KILLEEN, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Centex Technologies is proud to announce that John Sharp, former Chancellor of the Texas A…

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead …

Revenue Cycle Management Market to Hit $105.35 Billion by 2030: The Backbone of Healthcare Finance | MarketsandMarkets™
Delray Beach, FL, July 25, 2025 (GLOBE NEWSWIRE) -- Smarter Revenue, Stronger Care: Why Revenue Cycle Management Is Now Non-Negotiable The global revenue cycle management market, valued at US$54.97 billion in 2024, stood at US$61.11 billion in 2025 and is …

Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family VYJUVEK is the first and only genetic medicine approved in Japan for the …